Cao Huijuan, Wu Ruohan, Han Mei, Caldwell Patrina Ha Yuen, Liu Jian-Ping
College of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Centre for Kidney Research & Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead and Discipline of Paediatrics and Child Health, University of Sydney, Sydney, Australia.
PLoS One. 2017 Jul 18;12(7):e0180746. doi: 10.1371/journal.pone.0180746. eCollection 2017.
About 85.3% of hemolytic disease of the newborn (HDN) is caused by maternal-fetal ABO blood group incompatibility. However, there is currently no recommended "best" therapy for ABO incompatibility during pregnancy.
To systematically assess the safety and effectiveness of oral Chinese herbal medicine (CHM) for preventing HDN due to ABO incompatibility.
The protocol of this review was registered on the PROSPERO website (No. CRD42016038637).Six databases were searched from inception to April 2016. Randomized controlled trials (RCTs) of CHM for maternal-fetal ABO incompatibility were included. The primary outcome was incidence of HDN. The Cochrane risk of bias tool was used to assess the methodological quality of included trials. Risk ratios (RR) and mean differences with 95% confidence interval were used as effect measures. Meta-analyses using Revman 5.3 software were conducted if there were sufficient trials without obvious clinical or statistical heterogeneity available.
Totally 28 RCTs involving3413 women were included in the review. The majority of the trials had unclear or high risk of bias. Our study found that the rate of HDN and the incidence of neonatal jaundice might be 70% lower in the herbal medicine group compared with the usual care group (RR from 0.25 to 0.30).After treatment with herbal medicine, women were twice as likely to have antibody titers lower than 1:64 compared with women who received usual care(RR from 2.15 to 3.14) and the umbilical cord blood bilirubin level in the herbal medicine group was 4umol/L lower than in those receiving usual care. There was no difference in Apgar scores or birthweights between the two groups.
This review found very low-quality evidence that CHM prevented HDN caused by maternal-fetal ABO incompatibility. No firm conclusions can be drawn regarding the effectiveness or safety of CHM for this condition.
约85.3%的新生儿溶血病(HDN)由母胎ABO血型不合引起。然而,目前尚无针对孕期ABO血型不合的推荐“最佳”治疗方法。
系统评价口服中药预防ABO血型不合所致HDN的安全性和有效性。
本综述方案已在PROSPERO网站注册(注册号CRD42016038637)。检索了6个数据库,检索时间从建库至2016年4月。纳入中药治疗母胎ABO血型不合的随机对照试验(RCT)。主要结局为HDN发病率。采用Cochrane偏倚风险工具评估纳入试验的方法学质量。效应量采用风险比(RR)和95%置信区间的均值差。如果有足够数量的试验且无明显临床或统计学异质性,则使用Revman 5.3软件进行Meta分析。
本综述共纳入28项RCT,涉及3413名女性。大多数试验存在不明确或高偏倚风险。我们的研究发现,与常规治疗组相比,中药组的HDN发生率和新生儿黄疸发生率可能低70%(RR为0.25至0.30)。中药治疗后,与接受常规治疗的女性相比,抗体效价低于1:64的可能性是其两倍(RR为2.15至3.14),且中药组脐血胆红素水平比接受常规治疗的组低4μmol/L。两组间阿氏评分或出生体重无差异。
本综述发现极低质量的证据表明中药可预防母胎ABO血型不合所致的HDN。关于中药治疗这种情况的有效性或安全性,无法得出确凿结论。